default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

SK Chemicals awarded ‘2017 New Drug Grand Prize’

Lee Han-soo  Published 2017.09.22  11:49  Updated 2017.09.22 11:49

공유
default_news_ad2

SK Chemicals said Thursday that it has received the “2017 New Drug Grand Prize” from the Ministry of Food and Drug Safety.

“This is recognition of SK Chemicals’ innovative R&D achievements in the biotechnology field such as vaccines and blood products,” the company said in a statement.

Ahn Jae-yong, head of SK Chemicals vaccine business department, accepting the 2017 New Drug Grand Prize on Thursday

SK Chemicals SK케미칼 has commercialized Skycellflu, the world's first quadrivalent cell culture flu vaccine, and developed Afstyla2, the next-generation hemophilia treatment, which became the first Korean biopharmaceutical drug to enter the U.S. and Europe.

Skycellflu is a next-generation vaccine that can prevent four kinds of influenza viruses. It can prevent two kinds of influenza A virus (H1N1, H3N2) and two types of B virus (Yamagata, Victoria).

Afstyla2 is the world’s first recombinant Factor VIII blood coagulation medication, which is a single-chain product. The existing hemophilia treatment was a combination of two separate proteins, but Afstyla2 completely combines the two proteins to improve stability and maintains continuous bleeding management when taken twice a week.

The company is also developing a vaccine against diseases such as pneumococci, cervical cancer, and childhood enteritis that have not become self-sufficient in Korea, while their shingles vaccine is waiting for the final marketing approval from the ministry.

“Since 2008, the company has concentrated on R&D capabilities for vaccine development and has accumulated differentiated technologies,” said Ahn Jae-yong 안재용, head of SK Chemicals vaccine business department. “We will contribute to the promotion of human health and the development of bio-industry by introducing more various vaccines in the future.”

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch